Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.

1. Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellström D, Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008;93:1101-3. 2. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont E, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-92. 3. Hesse V, Jaeger U, Vogel H, Kronmeyer Z, Zeliner K, Bernhardt I, et al. Data on growth of German children from birth up to 18 years. Sozialpaediatrie 1997;19:20-2. 4. van der Sluis IM, Hop WC, van Leeuwen JPTM, Pols HA, de Muinck, Keizer-Schrama SM. A cross sectional study on biochemical parameters of bone turnover and vitamin D metabolites in healthy Dutch children and young adults. Horm Res 2002;57:170-9. 5. Yang L, Drey V. Pediatric reference intervals for bone markers. Clin Biochem 2006;39:561-8. 6. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant 2008;42 (Suppl 2):S40-6. 7. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006-13. 8. O’Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679-89. 9. Osorio S, Noblejas AG, Duran A, Stegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007; 82:394-5. 10. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111:2538-47. 11. Suttorp M, Boehme J, Vaitl J, Mosch B, Pursche S, Jung R, et al. Side effects on the heart and skeleton of growing mice attributed to chronic imatinib exposure. Blood 2008;112:402[Abstract]. 12. Mariani S, Giona F, Basciani S, Brama M, Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008;372: 111-2. 13. Fujimoto S, Kubo T, Tanaka H, Miura M, Seino Y. Urinary pyridinoline and desoxy pyridinoline in healthy children and in children with growth hormone deficiency. J Clin Endocrinol Metabol 1995;80:1922-8.